Relationship Between Immunological Factors and Hemarthrosis in Hemophiliacs in Antananarivo Madagascar
International Journal of Immunology
Volume 7, Issue 4, December 2019, Pages: 47-50
Received: Jan. 14, 2020;
Accepted: Jan. 27, 2020;
Published: Feb. 13, 2020
Views 476 Downloads 148
Rakotomalala Toky Randriamahazo, Laboratory of Immunology, Joseph Ravoahangy Andrianavalona University Hospital Center (JRA UHC) Antananarivo, Madagascar
Zoliarisoa Ramihajamanana, Laboratory of Hematology, Joseph Ravoahangy Andrianavalona University Hospital Center (JRA UHC) Antananarivo, Madagascar
Anjatiana Annick Raherinaivo, Laboratory of Immunology, Joseph Ravoahangy Andrianavalona University Hospital Center (JRA UHC) Antananarivo, Madagascar
Miora Rasamindrakotroka, Laboratory of Immunology, Joseph Ravoahangy Andrianavalona University Hospital Center (JRA UHC) Antananarivo, Madagascar
Davidra Rajaonatahina, Laboratory of Immunology, Joseph Ravoahangy Andrianavalona University Hospital Center (JRA UHC) Antananarivo, Madagascar
Olivat Rakoto Alson, Laboratory of Hematology, Joseph Ravoahangy Andrianavalona University Hospital Center (JRA UHC) Antananarivo, Madagascar
Andry Rasamindrakotroka, Laboratory of Immunology, Joseph Ravoahangy Andrianavalona University Hospital Center (JRA UHC) Antananarivo, Madagascar
Follow on us
Currently, there are 122 hemophiliacs in Madagascar followed at the hemophiliac treatment center of the Joseph Ravoahangy Andrianavalona University Hospital Center (JRA UHC), 55 present hemophilia B and 67 of hemophilia A. In hemophilic patients, the diagnosis of hemarthrosis is obviousin front of articular inflammation. It’s important to determinate the main risk factor as well as predisposition indicators tothe occurrence of "spontaneous" hemarthrosis in hemophiliacsfor prevention andearly careanticipation. In this prospect, the search for potentpredisposition indicator such as immunologicalfactorsis important. This is a case control study on all hemophiliacs seen at (JRA UHC) with hemarthrosis for 7 months. We have descriptively studied the qualitative and quantitative variables consisting in the determination of rheumatoid factors (RF) and the titer of antistreptolysin O (ASLO). Then we studied the statistical correlations. During the study period, we included 30 hemophiliac subjects with hemarthrosis who had an average age of 16.8 years. We had as much hemophiliac A as hemophiliac B; 23.3% practiced sporting activity; 10% had history of angina, involvement of the knee joint predominated at 44% (left 24%). RF positive were present in 26.7% (8/30) predominant in hemophiliacs aged from 19 to 36 (62.5%). The ASLO positive titer was found in 43.3% (13/30) predominant in children from 5 to 13 years (38.5%) with a maximum rate of 1600IU / l. There was no significant relationship between the positivity of the parameters with the presence or absence of hemarthrosis with a value of p = 0.231 and p = 0.06 respectively (p > 0.05). A large number of hemophiliac patients had a combination of clinical and biological signs in relation to diagnose rheumatic fever and rheumatoid arthritis which must be monitored as this could predict the occurrence in the short and medium term of these diseases which could be mistaken for hemarthrosisrelated to hemophilia.
Hemophilia, Hemarthrosis, Rheumatoid Factor, Antistreptolysin O
To cite this article
Rakotomalala Toky Randriamahazo,
Anjatiana Annick Raherinaivo,
Olivat Rakoto Alson,
Relationship Between Immunological Factors and Hemarthrosis in Hemophiliacs in Antananarivo Madagascar, International Journal of Immunology.
Vol. 7, No. 4,
2019, pp. 47-50.
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Srivastava, A., Brewer, A. K., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., Street, A. (2013). Guidelines for the management of hemophilia. Haemophilia, 19 (1), e1-e47.
Dajani, A. S., Ayoub, E., Bierman, F. Z., Bisno, A. L., Denny, F. W., Durack, D. T., &Karchmer, A. W. (1992). Guidelines for the diagnosis of rheumatic fever: Jones criteria, 1992 update. Jama, 268 (15), 2069-2073.
Peters MJL, Symmons DPM, McCarey D. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010; 69: 325–31.
D. Morillon, N. Boutry, X. Demondion, B. Duquesnoy, A. Cotten. Lésions musculosquelettiques dans l’hémophilie. EMC-Radiologie. 2004; 1: 283–292.
Alcalay, M., & Deplas, A. (2002). Prise en charge rhumatologique de l’hémophilie (première partie: manifestations articulaires). Revue du rhumatisme, 69 (9), 868-876.
Martins, Thomas B., Hoffman, James L., Augustine, Nancy H., et al. Comprehensive analysis of antibody responses to streptococcal and tissue antigens in patients with acute rheumatic fever. International immunology, 2008, vol. 20, no 3, p. 445-452.
Rajaonarison LHNON, FH Rabemanorintsoa, FR Ravelonarivo, OA RakotoAlson, A Ahmad. Profil épidemio-clinique et radiologique des atteintes ostéo-articulaires deshémophiles à Madagascar. Pan AfricanMedical Journal. 2014; 19: 287.
Terao C, Yamakawa N, Yano K, Markusse YM, Ikari K, Yoshida S, et al. Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. Arthritis & Rheumatology. 2015; 67 (12): 3113–23.
Orge E, Çefle A, Yazıcı A, Gürel-Polat N, Hulagu S. The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in non-arthritic patients with chronic hepatitis C infection. Rheumatol Int. 2010; 30: 485–8.
Deane KD, Norris JM, Holers VM. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010; 36 (2): 213–41.
Remus CR, Castillo-Ortiz JD, Aguilar-Lozano L, Padilla-Ibarra J, Sandoval-Castro C, Vargas-Serafin CO, et al. Autoantibodies in Prediction of the Development of Rheumatoid Arthritis Among Healthy Relatives of Patients With the Disease. Arthritis Rheum. 2015; 67 (11): 2837–44.
Ben-chetrit E, Moses AE, Agmon-levin N, Block C. Serum levels of antistreptolysin O antibodies : their role in evaluating rheumatic diseases. International journal of rheumatic diseases. 2012; 15 (1): 78–85.